A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel
Pierre Maison-Blanche, Jan B Vermorken, Tuncay Goksel, Jean-Pascal Machiels, Sanjiv Agarwala, Sylvie Rottey, Gedske Daugaard, Constantin Volovat, Max Scheulen, Lisa Sengeløv, Dana Grecea, Alexandru Eniu, Elke Jäger, Eyal Meiri, Stefano Cascinu, Dirk Strumberg, Gokhan Demir, Michael Clemens, Graziella Pinotti, Mario NardiTroy Guthrie, Emmanuelle Boelle, Emmanuelle Magherini
Dive into the research topics of 'A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel'. Together they form a unique fingerprint.